Advertisement

Forensic Toxicology

, Volume 37, Issue 1, pp 121–131 | Cite as

Simultaneous determination of selegiline, desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine in oral fluid by LC/MS/MS

  • Lizhu Chen
  • Yingjia Yu
  • Yang Wang
  • Ping XiangEmail author
  • Gengli DuanEmail author
Original Article

Abstract

Purpose

It is crucial for forensic analysis to differentiate clinical use from illegal abuse. Selegiline (SG) is mainly metabolized to desmethylselegiline (DM-SG), R-(−)-methamphetamine (R-MA) and R-(−)amphetamine (R-AM); while abused methamphetamine and amphetamine mainly contain the S-(+)-form. The aim of this study was to simultaneously determine SG, DM-SG, R/S-MA, and R/S-AM in human oral fluid (OF) and to differentiate clinical use from illegal use. We also aim to apply the present method to the OF samples from authentic cases in forensic toxicology.

Methods

Liquid–liquid extraction and liquid chromatography-tandem mass spectrometry operating in positive ion multiple-reaction monitoring mode were utilized. The chromatographic system consisted of a ChirobioticTM V2 column (2.1 mm × 250 mm, 5 μm) and a mobile phase of methanol containing 0.1% (v/v) glacial acetic acid and 0.02% (v/v) ammonium hydroxide.

Results and conclusions

The calibration curves were linear from 1 to 100 ng/mL, and r > 0.995 for all analytes with imprecisions ≤ 15% and accuracy between 85 and 115%. Extraction recoveries ranged from 46.3 to 104.7% with coefficient of variation (CV) ≤ 10.3% and matrix effects (MEs) ranged from 47.4 to 114.8% with CV ≤ 12.9%. The lower limit of quantification was 0.2 ng/mL for SG and DM-SG and 1.0 ng/mL for S-MA, R-MA, S-AM and R-AM. The present method is simple, rapid (accomplished in 12 min), sensitive, and validated by authentic samples.

Keywords

Oral fluid Chiral analysis R/S-methamphetamine R/S-amphetamine Selegiline Desmethylselegiline 

Notes

Acknowledgements

The authors are grateful to the Ministry of Science and Technology (2016YFC0800704), the National Natural Science Foundation of China (81772022, 81871531), the Science and Technology Commission of Shanghai Municipality (17DZ2273200/16DZ2290900), and Ministry of Finance, PR China (GY2017G-1) for their financial support of this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the international and/or national committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

References

  1. 1.
    Cone EJ, Huestis MA (2007) Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 1098:51–103.  https://doi.org/10.1196/annals.1384.037 CrossRefGoogle Scholar
  2. 2.
    Bosker WM, Huestis MA (2009) Oral fluid testing for drugs of abuse. Clin Chem 55(11):1910–1931.  https://doi.org/10.1373/clinchem.2008.108670 CrossRefGoogle Scholar
  3. 3.
    Heltsley R, DePriest A, Black DL, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ (2011) Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol 35(8):529–540CrossRefGoogle Scholar
  4. 4.
    Chu M, Gerostamoulos D, Beyer J, Rodda L, Boorman M, Drummer OH (2012) The incidence of drugs of impairment in oral fluid from random roadside testing. Forensic Sci Int 215(1–3):28–31.  https://doi.org/10.1016/j.forsciint.2011.05.012 CrossRefGoogle Scholar
  5. 5.
    Bush DM (2008) The US mandatory guidelines for federal workplace drug testing programs: current status and future considerations. Forensic Sci Int 174(2–3):111–119.  https://doi.org/10.1016/j.forsciint.2007.03.008 CrossRefGoogle Scholar
  6. 6.
    Huestis MA, Cone EJ (2004) Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28(6):394–399CrossRefGoogle Scholar
  7. 7.
    Mohamed KM, Al-Hazmi AH, Alasiri AM, Ali Mel S (2016) A GC-MS Method for Detection and Quantification of Cathine, Cathinone, Methcathinone and Ephedrine in Oral Fluid. J Chromatogr Sci 54(8):1271–1276.  https://doi.org/10.1093/chromsci/bmw082 CrossRefGoogle Scholar
  8. 8.
    Newmeyer MN, Concheiro M, da Costa JL, Flegel R, Gorelick DA, Huestis MA (2015) Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal l-methamphetamine administration. Drug Test Anal 7(10):877–883.  https://doi.org/10.1002/dta.1784 CrossRefGoogle Scholar
  9. 9.
    Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH (2003) A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna) 110(11):1241–1255.  https://doi.org/10.1007/s00702-003-0036-4 CrossRefGoogle Scholar
  10. 10.
    Katagi M, Tatsuno M, Miki A, Nishikawa M, Nakajima K, Tsuchihashi H (2001) Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 759(1):125–133CrossRefGoogle Scholar
  11. 11.
    Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O (2003) Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 31(9):1093–1102.  https://doi.org/10.1124/dmd.31.9.1093 CrossRefGoogle Scholar
  12. 12.
    Siu EC, Tyndale RF (2008) Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 324(3):992–999.  https://doi.org/10.1124/jpet.107.133900 CrossRefGoogle Scholar
  13. 13.
    Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2016) Postmortem redistribution of methamphetamine and amphetamine in blood specimens from various blood vessels and in the specimens from pericardial fluid, bile, stomach contents and various solid tissues collected from a human cadaver. Forensic Toxicol 34(1):191–198.  https://doi.org/10.1007/s11419-015-0303-8 CrossRefGoogle Scholar
  14. 14.
    Makino Y, Suzuki A, Ogawa T, Shirota O (1999) Direct determination of methamphetamine enantiomers in urine by liquid chromatography with a strong cation-exchange precolumn and phenyl-beta-cyclodextrin-bonded semi-microcolumn. J Chromatogr B Biomed Sci Appl 729(1–2):97–101CrossRefGoogle Scholar
  15. 15.
    Maurer HH, Kraemer T (1992) Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch Toxicol 66(9):675–678CrossRefGoogle Scholar
  16. 16.
    Liu Y, Hao B, Shi Y, Xue L, Wang X, Chen Y, Zhao H (2017) Violent offences of methamphetamine users and dilemmas of forensic psychiatric assessment. Forensic Sci Res 2(1):11–17CrossRefGoogle Scholar
  17. 17.
    Reimer ML, Mamer OA, Zavitsanos AP, Siddiqui AW, Dadgar D (1993) Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 22(4):235–242.  https://doi.org/10.1002/bms.1200220404 CrossRefGoogle Scholar
  18. 18.
    Heinonen EH, Anttila MI, Lammintausta RA (1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56(6 Pt 2):742–749CrossRefGoogle Scholar
  19. 19.
    Esposito FM, Crumpton S, Mitchell J, Flegel RR (2012) Evaluation of the 20% D-methamphetamine requirement for determining illicit use of methamphetamine in urine. J Anal Toxicol 36(6):399–404.  https://doi.org/10.1093/jat/bks042 CrossRefGoogle Scholar
  20. 20.
    Mohr S, Weiss JA, Spreitz J, Schmid MG (2012) Chiral separation of new cathinone- and amphetamine-related designer drugs by gas chromatography-mass spectrometry using trifluoroacetyl-l-prolyl chloride as chiral derivatization reagent. J Chromatogr A 1269:352–359.  https://doi.org/10.1016/j.chroma.2012.09.079 CrossRefGoogle Scholar
  21. 21.
    Segawa H, Iwata YT, Yamamuro T, Kuwayama K, Tsujikawa K, Kanamori T, Inoue H (2017) Enantioseparation of methamphetamine by supercritical fluid chromatography with cellulose-based packed column. Forensic Sci Int 273:39–44.  https://doi.org/10.1016/j.forsciint.2017.01.025 CrossRefGoogle Scholar
  22. 22.
    Sevcik J, Stransky Z, Ingelse BA, Lemr K (1996) Capillary electrophoretic enantioseparation of selegiline, methamphetamine and ephedrine using a neutral beta-cyclodextrin epichlorhydrin polymer. J Pharm Biomed Anal 14(8–10):1089–1094CrossRefGoogle Scholar
  23. 23.
    Weiss JA, Kadkhodaei K, Schmid MG (2017) Indirect chiral separation of 8 novel amphetamine derivatives as potential new psychoactive compounds by GC-MS and HPLC. Sci Justice 57(1):6–12.  https://doi.org/10.1016/j.scijus.2016.08.007 CrossRefGoogle Scholar
  24. 24.
    Hadener M, Bruni PS, Weinmann W, Frubis M, Konig S (2017) Accelerated quantification of amphetamine enantiomers in human urine using chiral liquid chromatography and on-line column-switching coupled with tandem mass spectrometry. Anal Bioanal Chem 409(5):1291–1300.  https://doi.org/10.1007/s00216-016-0056-1 CrossRefGoogle Scholar
  25. 25.
    Wang T, Shen B, Shi Y, Xiang P, Yu Z (2015) Chiral separation and determination of R/S-methamphetamine and its metabolite R/S-amphetamine in urine using LC-MS/MS. Forensic Sci Int 246:72–78.  https://doi.org/10.1016/j.forsciint.2014.11.009 CrossRefGoogle Scholar
  26. 26.
    Kronstrand R, Ahlner J, Dizdar N, Larson G (2003) Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 27(3):135–141CrossRefGoogle Scholar
  27. 27.
    Nishida K, Itoh S, Inoue N, Kudo K, Ikeda N (2006) High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. J Anal Toxicol 30(4):232–237CrossRefGoogle Scholar
  28. 28.
    Leis HJ, Fauler G, Windischhofer W (2014) Enantioselective quantitative analysis of amphetamine in human plasma by liquid chromatography/high-resolution mass spectrometry. Anal Bioanal Chem 406(18):4473–4480.  https://doi.org/10.1007/s00216-014-7850-4 CrossRefGoogle Scholar
  29. 29.
    Borg D, Kolb E, Lantigua C, Stripp R (2018) Chiral analysis of methamphetamine in oral fluid samples: a method to distinguish licit from illicit drug use. J Anal Toxicol 42(1):25–32.  https://doi.org/10.1093/jat/bkx079 CrossRefGoogle Scholar
  30. 30.
    Newmeyer MN, Concheiro M, Huestis MA (2014) Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. J Chromatogr A 1358:68–74.  https://doi.org/10.1016/j.chroma.2014.06.096 CrossRefGoogle Scholar
  31. 31.
    Malakova J, Pavek P, Svecova L, Jokesova I, Zivny P, Palicka V (2009) New high-performance liquid chromatography method for the determination of (R)-warfarin and (S)-warfarin using chiral separation on a glycopeptide-based stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci 877(27):3226–3230.  https://doi.org/10.1016/j.jchromb.2009.07.009 CrossRefGoogle Scholar
  32. 32.
    Alyamani M, Li Z, Upadhyay SK, Anderson DJ, Auchus RJ, Sharifi N (2017) Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol 172:231–239.  https://doi.org/10.1016/j.jsbmb.2016.04.002 CrossRefGoogle Scholar
  33. 33.
    Yu J, Tang J, Yuan X, Guo X, Zhao L (2017) Evaluation of the chiral recognition properties and the column performances of three chiral stationary phases based on cellulose for the enantioseparation of six dihydropyridines by high-performance liquid chromatography. Chirality 29(3–4):147–154.  https://doi.org/10.1002/chir.22690 CrossRefGoogle Scholar
  34. 34.
    Ribeiro AR, Maia AS, Cass QB, Tiritan ME (2014) Enantioseparation of chiral pharmaceuticals in biomedical and environmental analyses by liquid chromatography: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 968:8–21.  https://doi.org/10.1016/j.jchromb.2014.02.049 CrossRefGoogle Scholar
  35. 35.
    Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C (2007) Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol 47(10):1256–1267.  https://doi.org/10.1177/0091270007304779 CrossRefGoogle Scholar
  36. 36.
    Kronstrand R, Andersson MC, Ahlner J, Larson G (2001) Incorporation of selegiline metabolites into hair after oral selegiline intake. J Anal Toxicol 25(7):594–601CrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Analysis, School of PharmacyFudan UniversityShanghaiChina
  2. 2.Department of Forensic Toxicology, Ministry of Justice, Shanghai Key Laboratory of Forensic MedicineAcademy of Forensic SciencesShanghaiChina

Personalised recommendations